. Author manuscript; available in PMC: 2022 Sep 20.

Published in final edited form as: Invest New Drugs. 2020 Jan 24;38(5):1550–1558. doi: 10.1007/s10637-020-00898-2

Table 4: Treatment Efficacy.

This table describes the treatment efficacy and patient outcomes

	n=18
Median PFS, days (range)	89 (36-406)
	2.9 months

6 month PFS, % (95% CI)¹	22% (7%,43%)

Median OS, days (range²)	142 (43-453)
	4.6 months

Best Overall Response Evaluation
Progressive Disease (PD), n (%)	10
Stable Disease (SD), n (%)	7
Partial Response (PR), n (%)	1

6 Week PFS, %	44%

12 Week Disease Control Rate (SD+PR+CR), % (95% CI)	33% (13%,59%)

^1-

6 month PFS and 95% confidence interval estimated using life-table method.

^2-

Denotes that the highest observation was censored at maximum